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Fanconi anemia (FA) is a rare genomic instability disorder characterized by progressive bonemarrow failure and predisposition to cancer.
FA-associated gene products are involved in the repair of DNA interstrand crosslinks (ICLs). Fifteen FA-associated genes have been
identified, but the genetic basis in some individuals still remains unresolved. Here, we used whole-exome and Sanger sequencing on
DNA of unclassified FA individuals and discovered biallelic germline mutations in ERCC4 (XPF), a structure-specific nuclease-encoding
gene previously connected to xeroderma pigmentosum and segmental XFE progeroid syndrome. Genetic reversion andwild-type ERCC4
cDNA complemented the phenotype of the FA cell lines, providing genetic evidence that mutations in ERCC4 cause this FA subtype.
Further biochemical and functional analysis demonstrated that the identified FA-causing ERCC4mutations strongly disrupt the function
of XPF in DNA ICL repair without severely compromising nucleotide excision repair. Our data show that depending on the type of
ERCC4 mutation and the resulting balance between both DNA repair activities, individuals present with one of the three clinically
distinct disorders, highlighting the multifunctional nature of the XPF endonuclease in genome stability and human disease.Fanconi anemia (FA) is characterized by bone marrow
failure (BMF), congenital malformations, hypersensitivity
to DNA interstrand crosslink (ICL)-inducing agents, chro-
mosome fragility, and a high susceptibility to cancer. Since
the discovery of the first FA-associated gene 20 years ago,
all together, 15 genes associated with FA have been identi-
fied; these include FANCA, FANCB, FANCC, FANCD1
(BRCA2), FANCD2, FANCE, FANCF, FANCG (XRCC9),
FANCI, FANCJ (BRIP1), FANCL (PHF9), FANCM, FANCN
(PALB2), FANCO (RAD51C), and FANCP (SLX4)1,2 (MIM
227650, 300514, 227645, 605724, 227646, 600901,
603467, 614082, 609053, 609054, 614083, 614087,
610832, 613390, and 613951, respectively). Studies to un-
ravel the genetic basis of this rare disorder uncovered a
genome-maintenance pathway that protects dividing cells
against replication-blocking DNA lesions. To identify addi-
tional FA-associated genes, we used the SOLiD 4 platform
for whole-exome sequencing on peripheral-blood DNA
from a Spanish FA individual (FA104) who was previously
excluded from all known FA complementation groups
(this study was approved by the Institutional Committee
on Ethical Research in Human Samples, and proper
informed consent was obtained). FA104 was born to unre-
lated parents and was diagnosed neonatally with a malfor-
mative syndrome suggestive of FA, the symptoms of which
included bilateral absent thumbs, microsomy, esophageal
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mality such as skin hyperpigmentation, photosensitivity,
sunlight-induced scarring, or atrophy. FA104 developed
BMF at the age of 2 years and died as a result of a hemor-
rhagic shock after bone marrow transplantation at the
age of 4 years. A positive chromosome-breakage test unam-
biguously confirmed the FA diagnosis: 92% of the cells
showed on average 4.4 diepoxybutane (DEB)-induced
breaks. Lymphoblasts from this individual were hypersen-
sitive to mitomycin-C (MMC) and melphalan but were
insensitive to the topoisomerase I inhibitor camptothecin
and the PARP inhibitor KU58948 (data not shown) and
showed normal FANCD2 monoubiquitination and
RAD51 focus formation.3 This suggests a defect down-
stream within the FA pathway, which does not involve ho-
mologous recombination. On the basis of a recessive mode
of inheritance, exome sequencing identified 17 candidate
disease genes for FA104 (Table S1, available online); of
these, ERCC4 (MIM 133520; also known as XPF) immedi-
ately caught our attention given the involvement of the
XPF-ERCC1-structure-specific nuclease in ICL repair.4
Both ERCC4 mutations were predicted to be pathogenic:
a 5 bp deletion in exon 8 (c.1484_1488delCTCAA) was pre-
dicted to lead to a frameshift and a premature stop codon
(p.Thr495Asnfs*6), and a missense mutation in exon 11
(c.2065C>A [p.Arg689Ser]; RefSeq accession numbers
NG_011442.1, NM_005236.2, and NP_005227.1) wasrobiology, Universitat Auto`noma de Barcelona, Bellaterra, 08193 Barcelona,
Salud Carlos III, Bellaterra, 08193 Barcelona, Spain; 3Department of Human
t of Clinical Genetics, VU University Medical Center, 1081 BT Amsterdam,
ony Brook University, Stony Brook, NY 11794-3400, USA; 6Department of
nds; 7Hematopoiesis and Gene Therapy Division, Centro de Investigaciones
tment of Bioinformatics, Sistemas Geno´micos SL, 46980 Valencia, Spain;
e Investigaciones Oncolo´gicas, E-28029 Madrid, Spain
rzburg.de (D.S.)
y of Human Genetics. All rights reserved.
013
Figure 1. ERCC4 Mutations and XPF
Deficiency in FA Individuals
(A) Sequence analysis of blood DNA from
FA104 revealed a missense mutation in
exon 11 (c.2065C>A [p. Arg689Ser]) (up-
per panel) and a 5 bp deletion in exon
8 leading to a frameshift and prema-
ture termination of translation (c.1484_
1488delCTCAA [p. Thr495Asnfs*6]) (lower
panel).
(B) Sequence analysis of blood DNA
from 1333 revealed a missense mutation
in exon 4 (c.689T>C [p.Leu230Pro])
(upper panel) and a 28 bp duplication
in exon 11 (lower panel) leading to a
frameshift and a premature stop codon
(c.2371_2398dup28 [p.Ile800Thrfs*24]).
(C) Immunoblot analysis showing XPF
expression in lymphoblasts from 1333
and FA104. Lymphoblasts from a healthy
individual (Con), the parents of 1333
(1333-F and 1333-M), and an unrelated
ERCC4mutation carrier (Het) were used as
controls. XPF levels are expressed as a ratio
relative to the loading control (RAD50).
(D) Genetic complementation of MMC
sensitivity in FA104 lymphoblasts by
wild-type XPF, but not by p.Arg689Ser
altered XPF. Site-directed mutagenesis
was used for introducing point muta-
tions into the pWPXL-XPF hemag-
glutinin (HA)-tagged plasmid with the
QuickChange method (Stratagene) as
described.5 Lentiviral supernatant produc-
tion and transduction were done as previ-
ously described,6 and cells were grown for
10 days in the presence of MMC. Data
represent a typical result of at least three
independent experiments.
(E) Genetic complementation of MMC sensitivity of 1333 lymphoblasts by wild-type XPF (experiments were performed as in D).
(F) MMC-induced growth inhibition of Ercc4-knockout MEFs transduced with lentiviral particles coding for GFP (negative control
vector), wild-type XPF, and p.Arg689Ser and p.Leu230Pro altered XPF. Data represent means and SD of at least three independent
experiments.predicted to change a highly conserved arginine within
the nuclease active site of XPF. Sanger sequencing on blood
DNA confirmed these mutations (Figure 1A) and their cor-
rect segregation (data not shown). In MMC-resistant
FA104 lymphoblasts (FA104R) obtained after long-term
exposure to a low dose of MMC, we detected a mutation
that restored the ERCC4 reading frame (Figure S1A), sup-
porting the notion that MMC sensitivity is due to ERCC4
mutations. Consistently, XPF levels were reduced in
FA104 lymphoblasts but were normalized in the reverted
FA104R lymphoblasts (Figure S1B). Immunoblotting did
not detect a truncated XPF, indicating that only the
p.Arg689Ser altered XPF was present in the FA104 cell line.
Sanger sequencing on 18 unclassified FA individuals
from Germany revealed biallelic ERCC4 mutations in
another individual (1333). Individual 1333 was born in
2002 and was unambiguously diagnosed with FA at the
age of 5 years as a result of multiple FA-related features,
such as perinatal growth retardation, short stature, pro-
nounced microcephaly, cafe´-au-lait spots, an ostium-pri-
mum defect, biliary atresia with fibrosis of the liver, BMF,The Amand a positive chromosome-fragility test (0.2, 6.7, and
9.4 breaks per cell at 0, 50, and 100 ng/ml MMC, respec-
tively). Individual 1333 is redheaded and has pale skin
color, but no spontaneous or UV-light-induced skin
lesions were reported at the age of 10 years. Similar to
those of FA104, lymphoblasts from individual 1333 were
normal with regard to FANCD2 monoubiquitination and
RAD51 focus formation and were sensitive to MMC and
melphalan but insensitive to the topoisomerase I inhibitor
camptothecin and to the PARP inhibitor KU58948 (data
not shown). Individual 1333 carries a 28 bp duplication
in exon 11 of the maternal allele (c.2371_2398dup28
[p.Ile800Thrfs*24]; Figure 1B), and this duplication is pre-
dicted to result in a truncated XPF that lacks the double
helix-hairpin-helix (HhH2) domain involved in heterodi-
merization with ERCC1 and DNA binding.7 The paternal
allele contains a missense mutation that changes a highly
conserved amino acid residue within the helicase-like
domain (c.689T>C [p. Leu230Pro]; Figure 1B). Immuno-
blot analysis showed that a missense altered XPF and a
truncated 90–95 kDa XPF are present at very low levelserican Journal of Human Genetics 92, 800–806, May 2, 2013 801
Figure 2. UV-Light and ICL Sensitivities
of ERCC4 Mutants Leading to FA
(A) UVC-light-induced apoptosis in FA104
lymphoblasts. Cells were analyzed for
UVC-light-induced apoptosis 24 hr after
irradiation with the use of the Annexin-
V-FLUOS Staining Kit (Roche). Data repre-
sent means and SD of at least three
independent experiments.
(B) UVC-light-induced growth inhibition
of human ERCC4-deficient immortal fibro-
blast cell lines (from XP individual XP2YO
and FA individual 1333) transduced with
lentiviral particles carrying cDNA coding
for wild-type XPF. The results are expressed
as a percentage of viable UVC-light-treated
cells relative to untreated controls. Data
represent means and SD of two indepen-
dent experiments.
(C) MMC sensitivity of human ERCC4-
deficient primary fibroblasts from XP, FA,
and XFE individuals (XP42RO, 1333, and
XP51RO, respectively). Data represent
means and SD of two independent experi-
ments.
(D) DEB-induced chromosome-fragility
test in human ERCC4-deficient primary
fibroblasts from XP, FA, and XFE individ-
uals (XP42RO, 1333, and XP51RO, respec-
tively).
(E) MMC-induced G2/M cell-cycle arrest
in the same cells as in (D). Experiments
presented in (D) and (E) were performed
as reported earlier.10(Figure 1C). As expected, the truncated XPF was undetect-
able with an antibody against the C-terminal HhH2
domain of XPF (amino acids 866–916, data not shown).
Interestingly, the truncated XPF was absent in a MMC-
resistant lymphoblastoid cell line (1333R) generated by
long-term exposure to MMC, and near-normal XPF levels
were detected in this reverted cell line (Figure S1C). PCR
amplification and sequence analysis revealed that the
28 bp duplication had disappeared in 1333R (Figure S1D)
and had thus restored the wild-type sequence. Both the in-
herited duplication and the somatic reversion might have
been triggered by an inverted 5 bp repeat flanking the
region.
Genetic complementation of MMC sensitivity in lym-
phoblasts from both FA individuals was achieved by lenti-
viral transduction of wild-type ERCC4 cDNA (Figures 1D
and 1E). In addition, we expressed wild-type and mutant
human ERCC4 cDNAs in embryonic fibroblasts (MEFs)
from Ercc4 (Xpf)-null mice. We found that ectopic expres-
sion of ERCC4 mutants encoding p.Leu230Pro and
p.Arg689Ser did not complementMMC sensitivity of these
MEFs (Figure 1F), providing additional evidence that the802 The American Journal of Human Genetics 92, 800–806, May 2, 2013ERCC4 missense mutations found in
both FA individuals inactivate XPF.
The genetic and functional data
show that mutations in ERCC4 cause
FA in two unrelated nonconsanguine-ous individuals. Because mutations in ERCC4 cause an
additional FA subtype (FA-Q), we propose FANCQ as an
alias for ERCC4.
ERCC4 mutations have been linked to the skin-photo-
sensitive and nucleotide excision repair (NER)-deficient
disorders xeroderma pigmentosum (XP [MIM 278700,
610651, 278720, 278730, 278740, 278760, 278780, and
278750])8 and XFE progeroid syndrome (MIM 610965),9
and we therefore tried to understand why the identified
ERCC4 variants specifically lead to FA. We hypothesized
that these mutants cause an FA phenotype because of a
strong deficiency in ICL repair but have sufficient NER
activity to prevent clinically relevant skin photosensitivity
and other NER-related features. Compared to an XP com-
plementation group C (XP-C) lymphoblast line, FA104
lymphoblasts were indeed not sensitive to UVC light
(Figure 2A). Given that UV-light survival experiments are
challenging in lymphoblastoid cell lines, we studied skin
fibroblasts from individual 1333 (FA104 fibroblasts were
not available) and found that the UV-light sensitivity in
FA individual 1333 was milder than that in XP comple-
mentation group F (XP-F) individual XP2YO (Figure 2B).
Figure 3. NER Analysis of ERCC4 Mutants In Vivo
(A and B) In primary fibroblasts, unscheduled DNA synthesis
(UDS) representing global NER activity was measured with 5-ethy-
nyl-deoxyuridine grossly as previously described.12
(A) XP-F (XP42RO) and FA (1333) cells (arrows) were compared to
mixed-in normal fibroblasts preloaded with polystyrene microbe-
ads (no arrows), used as an internal control. UDS signal was quan-
tified from 20–40 random XP-F or FA G1/G2 nuclei and expressed
as a percentage of control wild-type cells.
(B) UDS signals in Ercc4/ MEFs measured as in (A) are expressed
as a percentage of control wild-type MEFs. Ercc4/ cells were sta-
bly expressing an empty vector or one of various ERCC4 cDNAs
(wild-type or encoding p.Leu230Pro or p.Arg689Ser).
(C) Repair kinetics of UV-light-induced DNA damage by FA-
specific ERCC4 mutants in ERCC4- and NER-deficient human
cells (XP2YO). Cells expressing wild-type XPF, p.Arg689Ser or
p.Leu230Pro altered XPF, or XPF resulting from the 28 bp duplica-
tion were locally irradiated with UV light, cultured for the indi-
cated times, fixed and stained for 6-4 PPs, and tagged with HA
with the use of specific antibodies. Data represent the percentage
of cells with 6-4 PP spots at various time points; means and SD
of at least two independent experiments are shown. For each
experiment, 100 cells were counted.
The AmIn addition, the FA-specific XPF alterations p.Leu230Pro
and p.Arg689Ser rescued 100% of the UVC sensitivity
of XP2YO fibroblasts (Figure S2A) and approximately
80% of the UVC-light sensitivity of Ercc4-null MEFs
(Figure S2B) but were both unable to complement
MMC sensitivity (Figure 1F). Furthermore, XFE and 1333
fibroblasts responded typically like FA cells upon MMC-
induced survival (Figure 2C), DEB-induced chromosome
breakage (Figure 2D), and MMC-induced G2-phase arrest
(Figure 2E), whereas XP-F cells showed milder MMC sensi-
tivity and lacked DEB-induced chromosome fragility and
MMC-induced cell-cycle arrest (Figure 2C–2E). Previous
experiments in Chinese hamster ovary cells also demon-
strated that the XFE-specific p.Arg153Pro altered XPF
does not rescue MMC or UV-light sensitivity.11 Therefore,
we conclude that XP, XFE, and FA cells with ERCC4 muta-
tions clearly have a distinct response to UV light andMMC
(Table S2).
To further investigate the extent of NER deficiency in the
FA-affected individuals, we measured UV-light-induced
unscheduled DNA synthesis (UDS) in primary skin fibro-
blasts from individual 1333 and from an XP-F individual
(XP42RO) withmild clinical UV-light sensitivity and found
245 4% and 21 5 3% residual UDS activity, respectively
(Figure 3A). We also determined UDS in Ercc4-null MEFs
expressing the FA-specific XPF alterations p.Leu230Pro or
p.Arg689Ser. The levels of UDS activity were 39.7% and
48.4% of the normal mean for p.Leu230Pro and
p.Arg689Ser altered XPF, respectively (Figure 3B), enough
to complement 80% of UVC-light sensitivity of these
MEFs (Figure S2B). In XPF-deficient human XP2YO fibro-
blasts, p.Leu230Pro and p.Arg689Ser altered XPF rather
efficiently corrected the defective removal of 6-4 photo-
products (PPs) at sites of local UV damage (Figure 3C). In
contrast, XP2YO cells expressing the ERCC4 mutant with
the 28 bp duplication were completely deficient in NER
activity, as predicted from the disruption of the ERCC1-
and DNA-binding domain of this truncated protein. The
studies presented in Figures 2 and 3 demonstrate that FA
cells with ERCC4mutations are fully deficient in ICL repair
but retain significant levels of NER activity.
Cell lines from XP-F individuals show a characteristic
failure of the altered XPF to properly translocate to the
nucleus through aggregation of the protein in the cyto-
plasm.11 This feature is evident for XP-causing mutations
and accentuated in cells from the individual with XFE syn-
drome. However, FA-causing XPFmissense altered proteins
can actually translocate to the nucleus, where they are
recruited to sites of active NER (Figures S3A and S3B) and
can interact with SLX4 and ERCC1 (Figures S3C and
S3D). These results might be functionally important, given
that a recent article reports that SLX4 interaction with XPF
is crucial for ICL repair and that SLX4-knockout mice phe-
nocopy FA.13 Using Xenopus extracts, J.C. Walter’s group
reported that the FA upstream pathway genes are required
to regulate a nuclease that makes DNA incisions near the
ICL.14 Given that FA-specific altered XPF proteins canerican Journal of Human Genetics 92, 800–806, May 2, 2013 803
Figure 4. Nuclease Activity of Altered XPF
(A) NER activity of wild-type and altered ERCC1-XPF dimer. A
plasmid containing a site-specific 1,3-intrastrand cis-Pt DNA cross-
link was incubated with whole-cell extracts from HeLa cells or
XPF-deficient cells (XP2YO) complemented with recombinant
ERCC1-XPF purified from Sf9 insect cells as reported.13 The
excised DNA fragments of 24–32 nucleotides are shown. The posi-
tion of a 25-mer is indicated.
(B) Incision of a stem-loop substrate with wild-type and altered
XPF. The 30 Cy5-labeled substrate was incubated with recombinant
ERCC1-XPF in the presence of 2mMMgCl2 or 0.4mMMnCl2, and
the products were analyzed by denaturing PAGE. The incision
reaction was performed essentially as described earlier.5,11reach the site of damage, we then investigated their ability
to cleave DNA. For this aim, the p.Arg689Ser altered XPF
was purified as a heterodimer with ERCC1 as previously
described.5 Subsequently, NER reactions were performed
with the purified altered protein, extracts from XPF-defi-
cient XP2YO cells, and a plasmid containing an NER
substrate (1,3-cisplatin intrastrand crosslink).15 Consistent
with the functional data above, the purified heterodimer
composed of ERCC1 and p.Arg689Ser XPF is proficient
in the excision step of NER similarly to wild-type XPF,
given that it restored the ability to cleave and remove the
site-specific intrastrand crosslink from the plasmid in
XP2YO cell extracts (Figure 4A). Nevertheless, the excision
reaction is not perfect given that the excised fragments
are, on average, 1 nucleotide longer than expected from
a normal reaction with wild-type-XPF-ERCC1 dimer (Fig-
ure 4A, lane 4). We also performed in vitro nuclease804 The American Journal of Human Genetics 92, 800–806, May 2, 2activity assays with purified ERCC1-p.Arg689Ser-XPF
and ERCC1-p.Arg689Ala-XPF on a stem-loop model
DNA substrate. Unlike wild-type XPF and altered XPF
proteins causing XP (p.Arg799Trp) or XFE progeroid syn-
drome (p.Arg153Pro),11 p.Arg689Ser XPF is unable to
cleave such a substrate (Figure 4B), indicating that the
nuclease-type activity of p.Arg689Ser XPF is grossly
abnormal. Unfortunately, we could not perform these
biochemical experiments with the p.Leu230Pro altered
XPF because we were unable to express and purify
ERCC1-p.Leu230Pro-XPF as a result of its low stability
and tendency to aggregate. We finally checked whether
the FA-specific altered XPF proteins ectopically expressed
in Ercc4-null MEFs can perform the incision step of ICL
repair. Both p.Leu230Pro and p.Arg689Ser altered XPF
completely restored the incision defect of Ercc4-null
MEFs, as measured by the COMET assay (data not shown),
but the cells remained hypersensitive to ICLs (Fig-
ure 1F). Although additional biochemical experiments
are required, our results suggest that the ICL sensitivity
of individuals FA104 and 1333 is not directly linked to
the absence of XPF nuclease activity. It seems unlikely
that the defect is a downstream step of homologous recom-
bination because FA104 and 1333 cells are not sensitive
to PARP inhibitors and are normal in Rad51 focus forma-
tion. Given that the nuclease activity of the FA-specific
p.Arg689Ser altered XPF is grossly abnormal, it is tempting
to speculate that the ICL-unhooking step in these FA cells
leaves an intermediate aberrant substrate that is irreparable
by subsequent ICL-repair factors.
Our genetic, biochemical, and functional studies, along
with the characterization of previous ERCC4 mutations
causing XP-F and XFE, provide amodel for themechanistic
understanding of how mutations in ERCC4 lead to three
distinct diseases (Table S2). Most of the presently known
XP-F individuals suffer from a relatively mild form of
XP.16 Cells from these individuals have a reduced level of
XPF in the nucleus because the altered XPF has a tendency
to aggregate in the cytoplasm.11 This reduced level of
nuclear XPF is insufficient to mediate complete NER, but
it still has enough ICL-repair-specific functions to prevent
chromosome fragility, cell-cycle arrest, and subsequent
FA clinical manifestations. A second set of ERCC4 muta-
tions, characterized in this study, allow localization of
the protein to the nucleus, where they exert a certain level
of NER activity but are fully deficient in ICL repair.
p.Arg689Ser XPF is a stable and NER-proficient protein
with an active site structure that prevents it from properly
processing ICL-repair intermediates. p.Leu230Pro XPF is
more similar to the products of previously described
ERCC4 mutations in that it is less stable and might have
a tendency to aggregate in the cytoplasm. However, suffi-
cient amounts of the protein are properly folded and reach
chromatin, where it appears to have some activity in the
removal of 6-4 PPs. Residual NER activity in the skin
tissue of individual 1333 in vivo might explain why this
individual has no clinically relevant skin photosensitivity,013
although we cannot exclude that dermatological problems
will arise later in life. A final category of ERCC4 mutations
is associated with XFE progeroid syndrome, which is char-
acterized by very low levels of nuclear XPF, apparently
insufficient to support either NER or ICL repair. Impor-
tantly, the only XFE-affected individual described suffered
from both skin photosensitivity and anemia9,16 and shared
some cellular features with XP (NER defect and UV-light
sensitivity) and FA (extreme ICL sensitivity, DEB-induced
chromosome fragility, andMMC-induced cell-cycle arrest),
suggesting that XFE syndrome is characterized by a
combination of XP and FA manifestations (Table S2).
Exhaustion of hematopoietic stem cells is also an attribute
of ERCC1-XPF hypomorphic mice that mimic XFE (Laura
Niedernhofer, personal communication). Microsomy,
microcephaly, and liver fibrosis were likewise observed in
FA individual 1333, in Ercc1- and Ercc4-deficient mice,
and in the unique ERCC1-deficient individual, who all
lack ICL-repair functions.17–21
In a broader sense, this study demonstrates that depend-
ing on the type of ERCC4 mutation and the balance
between NER and ICL-repair activities, affected individuals
present with one of three clinically distinct disorders.
This resembles the case of XPD, which is involved in XP
complementation group D, trichothiodystrophy (MIM
601675), or Cockayne syndrome (MIM 216400) depending
on the type of mutation,22 and highlights the value of
characterizing rare genetic disorders for gaining insight
into the mechanisms of genome maintenance and human
disease. XPF has a central role in preventing genome insta-
bility, cancer, BMF, developmental abnormalities, and pre-
mature aging. Like those of other breast and ovarian cancer
susceptibility genes mutated in FA,23,24 the product of
ERCC4 also acts downstream of FANCD2 monoubiquitina-
tion. Therefore, it is important to study FANCQ as a candi-
date gene in hereditary breast and ovarian cancer.Supplemental Data
Supplemental Data include three figures and two tables and can be
found with this article online at http://www.cell.com/AJHG.Acknowledgments
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